The latest version of the Senate Finance Committee’s drug pricing bill structures a requirement for manufacturer discounts on brands in Medicare Part D that may be more to biopharma’s liking, but the bill would still impose price inflation rebates on drugs covered by Medicare Parts D and B, a policy industry has opposed.
The bill’s co-authors, Sens. Chuck Grassley, R-IA, and Ron Wyden, D-OR, have been working on revisions that are aimed at generating broader support for the bill in the Senate